Scholarlink

<p>In this study, composite microparticles based on the poly(3-hydroxybutyrate-<i>co</i>-3-hydroxyvalerate) (P(3HB-<i>co</i>-3HV)) copolymer and natural polysaccharides (sodium alginate and chitosan succinate) were obtained the emulsion solvent evaporation method, including drug loaded formulations. The microparticles were evaluated in terms of particle size, polydispersity index, zeta potential (ζ-potential), encapsulation efficiency (<i>EE</i>), and surface morphology; in vitro ceftriaxone release kinetics was also investigated. The microparticles had a spherical shape with average diameters from 2.8 to 3.9&#xa0;μm and a negative ζ-potential ranging from − 9.5 to -18.1 mV. Modifying the P(3HB-<i>co</i>-3HV) matrix with sodium alginate or chitosan succinate improved ceftriaxone <i>EE</i>, reaching 44–59%. The P(3HB-<i>co</i>-3HV)/polysaccharide composite microparticles provided sustained release of ceftriaxone, which was well-fitted to the Korsmeyer–Peppas and Higuchi diffusion models. Furthermore, the ceftriaxone loaded P(3HB-<i>co</i>-3HV)/alginate composite microparticles exhibited pronounced antibacterial activity against both <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>. Overall, the ceftriaxone delivery systems in the form of microparticles based on P(3HB-<i>co</i>-3HV) and polysaccharides may be a promising platform for the development of new antibacterial therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Microbiological synthesis of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymer and production of composite microparticles with polysaccharides for prolonged delivery of ceftriaxone

  • 期刊论文

  • 发表日期：

    2026年7月15日

查看全文
  • Anastasiya Murueva,
  • Anna Shershneva,
  • Natalia Zhila,
  • Ekaterina Kessler,
  • Tatiana Volova

摘要

In this study, composite microparticles based on the poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (P(3HB-co-3HV)) copolymer and natural polysaccharides (sodium alginate and chitosan succinate) were obtained the emulsion solvent evaporation method, including drug loaded formulations. The microparticles were evaluated in terms of particle size, polydispersity index, zeta potential (ζ-potential), encapsulation efficiency (EE), and surface morphology; in vitro ceftriaxone release kinetics was also investigated. The microparticles had a spherical shape with average diameters from 2.8 to 3.9 μm and a negative ζ-potential ranging from − 9.5 to -18.1 mV. Modifying the P(3HB-co-3HV) matrix with sodium alginate or chitosan succinate improved ceftriaxone EE, reaching 44–59%. The P(3HB-co-3HV)/polysaccharide composite microparticles provided sustained release of ceftriaxone, which was well-fitted to the Korsmeyer–Peppas and Higuchi diffusion models. Furthermore, the ceftriaxone loaded P(3HB-co-3HV)/alginate composite microparticles exhibited pronounced antibacterial activity against both Staphylococcus aureus and Escherichia coli. Overall, the ceftriaxone delivery systems in the form of microparticles based on P(3HB-co-3HV) and polysaccharides may be a promising platform for the development of new antibacterial therapeutic strategies.